Patients with metastatic melanoma BrM treated withsingle-session SRS and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors(i), BRAFi, or conventional chemotherapy. Here, CTLA4 is linked to metastatic melanoma.